

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (currently amended) Reagent, ~~characterised~~ characterized in that, in at least two spatially separated positions on a cell-bound or soluble target molecule, ~~it~~ the reagent enters into interactions with ~~the latter said cell-bound or soluble target molecule or the nucleic acid coding for this;~~

wherein the reagent is selected from the group consisting of antibodies, antibody fragments, chimerized antibodies, humanised antibodies, single chain (sc)Fv fragments, scT-cell receptor (TCR) fragments, and hybrid scFv/scTCR fragments, ~~RNA and DNA aptamers and RNA and DNA Spiegelmers;~~

wherein said cell-bound or soluble target molecule is CD30; and

wherein said at least two spatially separated positions each comprise an epitope having a core sequence CEPDY, and the reagent enters into interactions with each of said at least two spatially separated positions on said cell-bound or soluble target molecule via binding to said epitope with a core sequence CEPDY.

Claims 2-5. (canceled)

6. (currently amended) Reagent according to one of the claim 1, ~~characterised~~ characterized in that the reagent is a chimerized antibody or a fragment of the same.

7. (currently amended) Reagent according to one of the claim 1, ~~characterised~~ characterized in that the reagent is available from a culture medium of the cell DSZ1 stored at the German Microorganisms Collection (DSM) under the number DSM ACC2548.

8. (currently amended) Reagent according to one of the claim 1, ~~eharacterised~~ characterized in that it also contains a toxin and/or a marking.

9. (currently amended) Reagent according to Claim 8, ~~eharacterised~~ characterized in that it is linked peptidically or via linker molecules with toxic proteins or with enzymes or proenzymes.

10. (withdrawn, currently amended) Reagent according to Claim 9, ~~eharacterised~~ characterized in that it is linked with toxins in the form of ribosome-inactivating proteins.

11. (currently amended) Reagent according to Claim 9, ~~eharacterised~~ characterized in that it is linked with enzymes from the group of the phosphodiesterases.

12. (withdrawn, currently amended) Reagent according to Claim 9, ~~eharacterised~~ characterized in that it is linked directly or via a linker molecule covalently or conjugated with radioactive isotopes.

13. (withdrawn, currently amended) Reagent according to Claim 12, ~~eharacterised~~ characterized in that the radioactive isotopes are selected from the group consisting of indium, iodine, yttrium, technetium, rhenium, copper and lutetium.

14. (withdrawn, currently amended) Reagent according to claim 8, ~~eharacterised~~ characterized in that it is linked directly or via linker molecules covalently or conjugated with photactivatable compounds.

15. (previously presented) Cell which produces a reagent according to claim 1.

16. (currently amended) Cell according to Claim 15, ~~eharacterised~~ characterized in that it contains a recombinant DNA which codes for the reagent or a part thereof.

17. (currently amended) Cell according to claim 15, ~~characterised~~ characterized in that it shows essential features of the cell as stored at the DSM under no. DSM ACC2548, especially the ability to give off the antibody in a considerably higher concentration into the medium than comparable cells.

18. (currently amended) Cell according to claim 15, ~~characterised~~ characterized in that it was stored at the DSM under the no. DSM ACC2548.

19. (withdrawn, currently amended) Method for the diagnosis especially of tumours and inflammatory diseases, ~~characterised~~ characterized in that a sample from the test person is ~~brought into~~ contacted with a reagent according to claim 1 and the extent of the reaction of the reagent with the sample is determined.

20. (withdrawn, currently amended) Method for the diagnosis of diseases, ~~characterised~~ characterized in that the diagnosis is carried out in vivo and that it covers, for example, a scintigraphy.

21. (withdrawn) A method of treating a patient having tumours, inflammatory, inflammatory-allergic and/or autoimmune diseases, comprising dispensing a reagent according to claim 1.

22. (withdrawn, currently amended) The method according to Claim 21, ~~characterised~~ characterized in that the tumour is a lymphoma or embryonal carcinoma.

23. (withdrawn, currently amended) The method according to Claim 22, ~~characterised~~ characterized in that the lymphoma is a CD30-positive lymphoma.

24. (withdrawn, currently amended) The method according to Claim 23, ~~characterised~~ characterized in that the CD30-positive lymphoma is a Hodgkin's lymphoma, an anaplastic large-cell lymphoma or an acute or lymphomatous form of adult T-cell leukaemia.

25. (withdrawn, currently amended) The method according to claim 21, ~~characterised~~ characterized in that 10 to 1000 mg/m² body surface of reagent is dispensed.

26. (withdrawn, currently amended) The method according to Claim 25, ~~characterised~~ characterized in that 20 to 400 mg/m² body surface of reagent is dispensed.

27. (withdrawn, currently amended) The method according to claim 21, ~~characterised~~ characterized in that the reagent is dispensed i.v.

28. (withdrawn, currently amended) A method of making a composition for the suppression or avoidance of a rejection reaction and/or a graft-versus-host reaction in the transplantation of organs, bone marrow or stem cells comprising incorporating a reagent according to claim 1 into a composition.

29. (previously presented) Pharmaceutical composition containing a reagent according to claim 1.

30. (previously presented) Kit for the diagnosis in particular of tumours, especially CD30-positive neoplasies, and inflammatory diseases, containing a reagent according to claim 1 together with instructions for use for the reagent.